Research programme - DNA topoisomerase inhibitors - Basilea Pharmaceutica

Drug Profile

Research programme - DNA topoisomerase inhibitors - Basilea Pharmaceutica

Alternative Names: BAL1; BAL2

Latest Information Update: 12 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Basilea Pharmaceutica
  • Class Antibacterials
  • Mechanism of Action DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Bacterial infections

Most Recent Events

  • 16 Jun 2016 Early research in Bacterial infections in Switzerland (unspecified route)
  • 16 Jun 2016 Antimicrobial data from in vitro studies released by Basilea Pharmaceutica
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top